Skip to content
2000
image of Polycystic Ovarian Syndrome (PCOS): A Brief Overview on Pathogenesis, Main Signaling Pathways, and Recent Studies Performed on Letrozoleinduced PCOS in Rodents

Abstract

Polycystic ovarian syndrome (PCOS) is a female endocrine and reproductive disease. The exact etiology remains unknown. There are several associated factors involved in the pathogenesis of PCOS, such as hyperandrogenism, insulin resistance, obesity, inflammation, oxidative stress, genetic, epigenetic, and environmental factors. However, the main diagnostic criteria involve at least two out of three symptoms, which are hyperandrogenism, polycystic ovaries, and menstrual cycle dysregulation. The treatment of the multiple symptoms of PCOS is still a medical challenge. Different molecular pathways have been studied in PCOS, such as PI3K-AKT, MAPK, NF-κB, and Keap-1-Nrf2 pathways, to visualize different mechanisms of action of this disease. In this regard, this review highlights the main signaling pathways involved in PCOS, as well as their associated studies retrieved from PubMed and Web of Science databases. In addition, several therapeutic approaches and targets that were tested on letrozole-induced PCOS in rodents were summarized and retrieved from the same databases over the past five years. For example, resveratrol, patuletin, adropin, mogroside V, Lepidium sativum seed extract, ascorbic acid, alendronate, probiotics, and mesenchymal stem cells, as well as lifestyle modifications, were shown to have positive effects in the management of PCOS. In conclusion, different approaches have been studied as potential treatments for PCOS according to different disease pathogeneses, molecular pathways, and associated symptoms, showing promising results that might be included in the PCOS therapeutic plan in the future.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpb/10.2174/0113892010433981251031050335
2026-02-23
2026-03-02

  • From This Site

    /content/journals/cpb/10.2174/0113892010433981251031050335
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Bozdag G. Mumusoglu S. Zengin D. Karabulut E. Yildiz B.O. The prevalence and phenotypic features of polycystic ovary syndrome: A systematic review and meta-analysis. Hum. Reprod. 2016 31 12 2841 2855 10.1093/humrep/dew218 27664216
    [Google Scholar]
  2. Escobar-Morreale H.F. Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment. Nat. Rev. Endocrinol. 2018 14 5 270 284 10.1038/nrendo.2018.24 29569621
    [Google Scholar]
  3. Sadeghi H.M. Adeli I. Calina D. Docea A.O. Mousavi T. Daniali M. Nikfar S. Tsatsakis A. Abdollahi M. Polycystic ovary syndrome: A comprehensive review of pathogenesis, management, and drug repurposing. Int. J. Mol. Sci. 2022 23 2 583 10.3390/ijms23020583 35054768
    [Google Scholar]
  4. Stener-Victorin E. Padmanabhan V. Walters K.A. Campbell R.E. Benrick A. Giacobini P. Dumesic D.A. Abbott D.H. Animal models to understand the etiology and pathophysiology of polycystic ovary syndrome. Endocr. Rev. 2020 41 4 bnaa010 10.1210/endrev/bnaa010 32310267
    [Google Scholar]
  5. Teede H.J. Tay C.T. Laven J.J.E. Dokras A. Moran L.J. Piltonen T.T. Costello M.F. Boivin J. Redman L.M. Boyle J.A. Norman R.J. Mousa A. Joham A.E. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2023 108 10 2447 2469 10.1210/clinem/dgad463 37580314
    [Google Scholar]
  6. Tetkova A. Susor A. Kubelka M. Nemcova L. Jansova D. Dvoran M. Del Llano E. Holubcova Z. Kalous J. Follicle-stimulating hormone administration affects amino acid metabolism in mammalian oocytes. Biol. Reprod. 2019 101 4 719 732 10.1093/biolre/ioz117 31290535
    [Google Scholar]
  7. Ożegowska K. Brązert M. Ciesiółka S. Nawrocki M.J. Kranc W. Celichowski P. Jankowski M. Bryja A. Jeseta M. Antosik P. Bukowska D. Skowroński M.T. Bruska M. Pawelczyk L. Zabel M. Nowicki M. Kempisty B. Genes involved in the processes of cell proliferation, migration, adhesion, and tissue development as new potential markers of porcine granulosa cellular processes in vitro: A microarray approach. DNA Cell Biol. 2019 38 6 549 560 10.1089/dna.2018.4467 31120353
    [Google Scholar]
  8. Shareghi-oskoue O. Aghebati-Maleki L. Yousefi M. Transplantation of human umbilical cord mesenchymal stem cells to treat premature ovarian failure. Stem Cell Res. Ther. 2021 12 1 454 10.1186/s13287‑021‑02529‑w 34380572
    [Google Scholar]
  9. Davis H.C. Hackney A.C. The hypothalamic-pituitary-ovarian axis and oral contraceptives: Regulation and function. Sex Hormones, Exercise and Women. 2nd ed Hackney A. Chapel Hill, NC, USA Springer 2017 1 10 10.1007/978‑3‑319‑44558‑8_1
    [Google Scholar]
  10. Owens L.A. Kristensen S.G. Lerner A. Christopoulos G. Lavery S. Hanyaloglu A.C. Hardy K. Yding Andersen C. Franks S. Gene expression in granulosa cells from small antral follicles from women with or without polycystic ovaries. J. Clin. Endocrinol. Metab. 2019 104 12 6182 6192 10.1210/jc.2019‑00780 31276164
    [Google Scholar]
  11. Naamneh Elzenaty R. du Toit T. Flück C.E. Basics of androgen synthesis and action. Best Pract. Res. Clin. Endocrinol. Metab. 2022 36 4 101665 10.1016/j.beem.2022.101665 35595638
    [Google Scholar]
  12. Bulsara J. Patel P. Soni A. Acharya S. A review: Brief insight into polycystic ovarian syndrome. Endocr Metab. Sci. 2021 3 100085
    [Google Scholar]
  13. Barrea L. Marzullo P. Muscogiuri G. Di Somma C. Scacchi M. Orio F. Aimaretti G. Colao A. Savastano S. Source and amount of carbohydrate in the diet and inflammation in women with polycystic ovary syndrome. Nutr. Res. Rev. 2018 31 2 291 301 10.1017/S0954422418000136 30033891
    [Google Scholar]
  14. Carson J.A. Manolagas S.C. Effects of sex steroids on bones and muscles: Similarities, parallels, and putative interactions in health and disease. Bone 2015 80 67 78 10.1016/j.bone.2015.04.015 26453497
    [Google Scholar]
  15. Ashraf S. Nabi M. Hyperandrogenism in polycystic ovarian syndrome and role of CYP gene variants: A review. Egypt. J. Med. Hum. Genet. 25 20 10.1186/s43042‑019‑0031‑4
    [Google Scholar]
  16. Karam M. Najjar H. El Sabban M. Hamade A. Najjar F. Regenerative medicine for polycystic ovary syndrome: Stem cell-based therapies and brown adipose tissue activation. Stem Cell Rev. Rep. 2023 19 4 853 865 10.1007/s12015‑023‑10505‑5 36633783
    [Google Scholar]
  17. Ye W. Xie T. Song Y. Zhou L. The role of androgen and its related signals in PCOS. J. Cell. Mol. Med. 2021 25 4 1825 1837 10.1111/jcmm.16205 33369146
    [Google Scholar]
  18. Wang K. Li Y. Chen Y. Androgen excess: A hallmark of polycystic ovary syndrome. Front. Endocrinol. 2023 14 1273542 10.3389/fendo.2023.1273542 38152131
    [Google Scholar]
  19. Liao B. Qiao J. Pang Y. Central regulation of PCOS: Abnormal neuronal-reproductive-metabolic circuits in PCOS pathophysiology. Front. Endocrinol. 2021 12 667422 10.3389/fendo.2021.667422 34122341
    [Google Scholar]
  20. Armanini D. Boscaro M. Bordin L. Sabbadin C. Controversies in the pathogenesis, diagnosis and treatment of PCOS: Focus on insulin resistance, inflammation, and hyperandrogenism. Int. J. Mol. Sci. 2022 23 8 4110 10.3390/ijms23084110 35456928
    [Google Scholar]
  21. Cara J.F. Fan J. Azzarello J. Rosenfield R.L. Insulin-like growth factor-I enhances luteinizing hormone binding to rat ovarian theca-interstitial cells. J. Clin. Invest. 1990 86 2 560 565 10.1172/JCI114745 2384603
    [Google Scholar]
  22. Chahal N. Geethadevi A. Kaur S. Lakra R. Nagendra A. Shrivastav T.G. De Pascali F. Reiter E. Crépieux P. Devi M.G. Malhotra N. Muralidhar K. Singh R. Direct impact of gonadotropins on glucose uptake and storage in preovulatory granulosa cells: Implications in the pathogenesis of polycystic ovary syndrome. Metabolism 2021 115 154458 10.1016/j.metabol.2020.154458 33278413
    [Google Scholar]
  23. Lonardo M.S. Cacciapuoti N. Guida B. Di Lorenzo M. Chiurazzi M. Damiano S. Menale C. Hypothalamic-ovarian axis and adiposity relationship in polycystic ovary syndrome: Physiopathology and therapeutic options for the management of metabolic and inflammatory aspects. Curr. Obes. Rep. 2024 13 1 51 70 10.1007/s13679‑023‑00531‑2 38172476
    [Google Scholar]
  24. Zeng X. Xie Y. Liu Y. Long S. Mo Z. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. Clin. Chim. Acta 2020 502 214 221 10.1016/j.cca.2019.11.003 31733195
    [Google Scholar]
  25. Salehi R. Mazier H.L. Nivet A.L. Reunov A.A. Lima P. Wang Q. Fiocco A. Isidoro C. Tsang B.K. Ovarian mitochondrial dynamics and cell fate regulation in an androgen-induced rat model of polycystic ovarian syndrome. Sci. Rep. 2020 10 1 1021 10.1038/s41598‑020‑57672‑w 31974436
    [Google Scholar]
  26. Fox C.W. Zhang L. Sohni A. Doblado M. Wilkinson M.F. Chang R.J. Duleba A.J. Inflammatory stimuli trigger increased androgen production and shifts in gene expression in theca-interstitial cells. Endocrinology 2019 160 12 2946 2958 10.1210/en.2019‑00588 31599939
    [Google Scholar]
  27. Li X. Qi J. Zhu Q. He Y. Wang Y. Lu Y. Wu H. Sun Y. The role of androgen in autophagy of granulosa cells from PCOS. Gynecol. Endocrinol. 2019 35 8 669 672 10.1080/09513590.2018.1540567 31056990
    [Google Scholar]
  28. Qiu X. Wei Y. Liu C. Ding C. Zhao S. Hyperandrogen enhances apoptosis of human ovarian granulosa cells via up-regulation and demethylation of PDCD4. Gynecol. Endocrinol. 2020 36 4 333 337 10.1080/09513590.2019.1653844 31423917
    [Google Scholar]
  29. Zhao H. Xing C. Zhang J. He B. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: A network meta-analysis. Reprod. Health 2021 18 1 171 10.1186/s12978‑021‑01207‑7 34407851
    [Google Scholar]
  30. Zhao H. Zhang J. Cheng X. Nie X. He B. Insulin resistance in polycystic ovary syndrome across various tissues: An updated review of pathogenesis, evaluation, and treatment. J. Ovarian Res. 2023 16 1 9 10.1186/s13048‑022‑01091‑0 36631836
    [Google Scholar]
  31. Chen W. Pang Y. Metabolic syndrome and PCOS: Pathogenesis and the role of metabolites. Metabolites 2021 11 12 869 10.3390/metabo11120869 34940628
    [Google Scholar]
  32. Cadagan D. Khan R. Amer S. Thecal cell sensitivity to luteinizing hormone and insulin in polycystic ovarian syndrome. Reprod. Biol. 2016 16 1 53 60 10.1016/j.repbio.2015.12.006 26952754
    [Google Scholar]
  33. Rice S. Christoforidis N. Gadd C. Nikolaou D. Seyani L. Donaldson A. Margara R. Hardy K. Franks S. Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Hum. Reprod. 2005 20 2 373 381 10.1093/humrep/deh609 15539436
    [Google Scholar]
  34. Ding H. Zhang J. Zhang F. Zhang S. Chen X. Liang W. Xie Q. Resistance to the insulin and elevated level of androgen: A major cause of polycystic ovary syndrome. Front. Endocrinol. 2021 12 741764 10.3389/fendo.2021.741764 34745009
    [Google Scholar]
  35. Wu S. Divall S. Nwaopara A. Radovick S. Wondisford F. Ko C. Wolfe A. Obesity-induced infertility and hyperandrogenism are corrected by deletion of the insulin receptor in the ovarian theca cell. Diabetes 2014 63 4 1270 1282 10.2337/db13‑1514 24379345
    [Google Scholar]
  36. Calcaterra V. Verduci E. Cena H. Magenes V.C. Todisco C.F. Tenuta E. Gregorio C. De Giuseppe R. Bosetti A. Di Profio E. Zuccotti G. Polycystic ovary syndrome in insulin‐resistant adolescents with obesity: The role of nutrition therapy and food supplements as a strategy to protect fertility. Nutrients 2021 13 6 1848 10.3390/nu13061848 34071499
    [Google Scholar]
  37. Li T. Mo H. Chen W. Li L. Xiao Y. Zhang J. Li X. Lu Y. Role of the PI3K-Akt signaling pathway in the pathogenesis of polycystic ovary syndrome. Reprod. Sci. 2017 24 5 646 655 10.1177/1933719116667606 27613818
    [Google Scholar]
  38. Si C. Wang N. Wang M. Liu Y. Niu Z. Ding Z. TMT-based proteomic and bioinformatic analyses of human granulosa cells from obese and normal-weight female subjects. Reprod. Biol. Endocrinol. 2021 19 1 75 10.1186/s12958‑021‑00760‑x 34016141
    [Google Scholar]
  39. Weisberg S.P. McCann D. Desai M. Rosenbaum M. Leibel R.L. Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 2003 112 12 1796 1808 10.1172/JCI200319246 14679176
    [Google Scholar]
  40. Oróstica L. Astorga I. Plaza-Parrochia F. Vera C. García V. Carvajal R. Gabler F. Romero C. Vega M. Proinflammatory environment and role of TNF-α in endometrial function of obese women having polycystic ovarian syndrome. Int. J. Obes. 2016 40 11 1715 1722 10.1038/ijo.2016.154 27569685
    [Google Scholar]
  41. Arkan M.C. Hevener A.L. Greten F.R. Maeda S. Li Z.W. Long J.M. Wynshaw-Boris A. Poli G. Olefsky J. Karin M. IKK-β links inflammation to obesity-induced insulin resistance. Nat. Med. 2005 11 2 191 198 10.1038/nm1185 15685170
    [Google Scholar]
  42. Xu J. Dun J. Yang J. Zhang J. Lin Q. Huang M. Ji F. Huang L. You X. Lin Y. Letrozole rat model mimics human polycystic ovarian syndrome and changes in insulin signal pathways. Med. Sci. Monit. 2020 26 923073 10.12659/MSM.923073 32638705
    [Google Scholar]
  43. Lainez N.M. Coss D. Obesity, neuroinflammation, and reproductive function. Endocrinology 2019 160 11 2719 2736 10.1210/en.2019‑00487 31513269
    [Google Scholar]
  44. Liu Q. Jiang J. Shi Y. Mo Z. Li M. Apelin/Apelin receptor: A new therapeutic target in Polycystic Ovary Syndrome. Life Sci. 2020 260 118310 10.1016/j.lfs.2020.118310 32835696
    [Google Scholar]
  45. Su X. Peng D. Adipokines as novel biomarkers of cardio-metabolic disorders. Clin. Chim. Acta 2020 507 31 38 10.1016/j.cca.2020.04.009 32283064
    [Google Scholar]
  46. Silvestris E. de Pergola G. Rosania R. Loverro G. Obesity as disruptor of the female fertility. Reprod. Biol. Endocrinol. 2018 16 1 22 10.1186/s12958‑018‑0336‑z 29523133
    [Google Scholar]
  47. Legro R.S. Dodson W.C. Kunselman A.R. Stetter C.M. Kris-Etherton P.M. Williams N.I. Gnatuk C.L. Estes S.J. Allison K.C. Sarwer D.B. Diamond M.P. Schlaff W.D. Casson P.R. Christman G.M. Barnhart K.T. Bates G.W. Usadi R. Lucidi S. Baker V. Zhang H. Eisenberg E. Coutifaris C. Dokras A. Benefit of delayed fertility therapy with preconception weight loss over immediate therapy in obese women with PCOS. J. Clin. Endocrinol. Metab. 2016 101 7 2658 2666 10.1210/jc.2016‑1659 27172435
    [Google Scholar]
  48. Gustafson B. Hammarstedt A. Andersson C.X. Smith U. Inflamed adipose tissue: A culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2007 27 11 2276 2283 10.1161/ATVBAHA.107.147835 17823366
    [Google Scholar]
  49. Ek I. Arner P. Rydén M. Holm C. Thörne A. Hoffstedt J. Wahrenberg H. A unique defect in the regulation of visceral fat cell lipolysis in the polycystic ovary syndrome as an early link to insulin resistance. Diabetes 2002 51 2 484 492 10.2337/diabetes.51.2.484 11812759
    [Google Scholar]
  50. Rudnicka E. Suchta K. Grymowicz M. Calik-Ksepka A. Smolarczyk K. Duszewska A.M. Smolarczyk R. Meczekalski B. Chronic low grade inflammation in pathogenesis of pcos. Int. J. Mol. Sci. 2021 22 7 3789 10.3390/ijms22073789 33917519
    [Google Scholar]
  51. Liu Y. Liu H. Li Z. Fan H. Yan X. Liu X. Xuan J. Feng D. Wei X. The release of peripheral immune inflammatory cytokines promote an inflammatory cascade in PCOS patients via altering the follicular microenvironment. Front. Immunol. 2021 12 685724 10.3389/fimmu.2021.685724 34079559
    [Google Scholar]
  52. Aboeldalyl S. James C. Seyam E. Ibrahim E.M. Shawki H.E.D. Amer S. The role of chronic inflammation in polycystic ovarian syndrome—a systematic review and meta-analysis. Int. J. Mol. Sci. 2021 22 5 2734 10.3390/ijms22052734 33800490
    [Google Scholar]
  53. Rostamtabar M. Esmaeilzadeh S. Tourani M. Rahmani A. Baee M. Shirafkan F. Saleki K. Mirzababayi S.S. Ebrahimpour S. Nouri H.R. Pathophysiological roles of chronic low‐grade inflammation mediators in polycystic ovary syndrome. J. Cell. Physiol. 2021 236 2 824 838 10.1002/jcp.29912 32617971
    [Google Scholar]
  54. Ibrahim Y.F. Alorabi M. Abdelzaher W.Y. Toni N.D.M. Thabet K. Hegazy A. Bahaa H.A. Batiha G.E.S. Welson N.N. Morsy M.A. Venugopala K.N. Abdel-Aziz A.M. Diacerein ameliorates letrozole-induced polycystic ovarian syndrome in rats. Biomed. Pharmacother. 2022 149 112870 10.1016/j.biopha.2022.112870 35367769
    [Google Scholar]
  55. Rudnicka E. Kunicki M. Suchta K. Machura P. Grymowicz M. Smolarczyk R. Inflammatory markers in women with polycystic ovary syndrome. BioMed Res. Int. 2020 2020 1 4092470 10.1155/2020/4092470 32219132
    [Google Scholar]
  56. Wang D. Weng Y. Zhang Y. Wang R. Wang T. Zhou J. Shen S. Wang H. Wang Y. Exposure to hyperandrogen drives ovarian dysfunction and fibrosis by activating the NLRP3 inflammasome in mice. Sci. Total Environ. 2020 745 141049 10.1016/j.scitotenv.2020.141049 32758727
    [Google Scholar]
  57. Mohammadi M. Oxidative stress and polycystic ovary syndrome: A brief review. Int. J. Prev. Med. 2019 10 1 86 10.4103/ijpvm.IJPVM_576_17 31198521
    [Google Scholar]
  58. Oyebanji O. Asaolu M. Assessment of antioxidant status of women with polycystic ovarian syndrome. Asian Pac. J. Reprod. 2020 9 1 9 15 10.4103/2305‑0500.275523
    [Google Scholar]
  59. Yan H. Wang L. Zhang G. Li N. Zhao Y. Liu J. Jiang M. Du X. Zeng Q. Xiong D. He L. Zhou Z. Luo M. Liu W. Oxidative stress and energy metabolism abnormalities in polycystic ovary syndrome: From mechanisms to therapeutic strategies. Reprod. Biol. Endocrinol. 2024 22 1 159 10.1186/s12958‑024‑01337‑0 39722030
    [Google Scholar]
  60. Forghani N. Karimi Z. Mokhtari M. Shariati M. Masjedi F. Association of oxidative stress with kidney injury in a hyperandrogenemic female rat model. Iran. J. Med. Sci. 2023 48 2 187 197 36895462
    [Google Scholar]
  61. Liu Y. Yu Z. Zhao S. Oxidative stress markers in the follicular fluid of patients with polycystic ovary syndrome correlate with a decrease in embryo quality. J. Assist. Reprod. Genet. 2023 38 2 471 477 10.1007/s10815‑020‑02014‑y
    [Google Scholar]
  62. Sun Y. Li S. Liu H. Bai H. Hu K. Zhang R. Liu Q. Fan P. Oxidative stress promotes hyperandrogenism by reducing sex hormone-binding globulin in polycystic ovary syndrome. Fertil. Steril. 2021 116 6 1641 1650 10.1016/j.fertnstert.2021.07.1203 34433519
    [Google Scholar]
  63. Sztretye M. Dienes B. Gönczi M. Astaxanthin: A potential mitochondrial-targeted antioxidant treatment in diseases and with aging. Oxid. Med. Cell. Longev. 2019 2019 3849692 10.1155/2019/3849692
    [Google Scholar]
  64. Amini L. Tehranian N. Movahedin M. Ramezani Tehrani F. Ziaee S. Antioxidants and management of polycystic ovary syndrome in Iran: A systematic review of clinical trials. Iran. J. Reprod. Med. 2015 13 1 1 8 25653669
    [Google Scholar]
  65. Murri M. Luque-Ramírez M. Insenser M. Ojeda-Ojeda M. Escobar-Morreale H.F. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): A systematic review and meta-analysis. Hum. Reprod. Update 2013 19 3 268 288 10.1093/humupd/dms059 23303572
    [Google Scholar]
  66. Dai M. Hong L. Yin T. Liu S. Disturbed follicular microenvironment in polycystic ovary syndrome: Relationship to oocyte quality and infertility. Endocrinology 2024 165 4 bqae023 10.1210/endocr/bqae023 38375912
    [Google Scholar]
  67. Fatima Q. Amin S. Kawa I.A. Jeelani H. Manzoor S. Rizvi S.M. Rashid F. Evaluation of antioxidant defense markers in relation to hormonal and insulin parameters in women with polycystic ovary syndrome (PCOS): A case-control study. Diabetes Metab. Syndr. 2019 13 3 1957 1961 10.1016/j.dsx.2019.04.032 31235121
    [Google Scholar]
  68. Chen Y. Yang J. Zhang L. The impact of follicular fluid oxidative stress levels on the outcomes of assisted reproductive therapy. Antioxidants 2023 12 12 2117 10.3390/antiox12122117 38136236
    [Google Scholar]
  69. Combs J.C. Hill M.J. Decherney A.H. Polycystic ovarian syndrome genetics and epigenetics. Clin. Obstet. Gynecol. 2021 64 1 20 25 10.1097/GRF.0000000000000581 33306497
    [Google Scholar]
  70. Khan M.J. Ullah A. Basit S. Genetic basis of polycystic ovary syndrome (PCOS): Current perspectives. Appl. Clin. Genet. 2019 12 249 260 10.2147/TACG.S200341 31920361
    [Google Scholar]
  71. Cao P. Yang W. Wang P. Li X. Nashun B. Characterization of DNA Methylation and Screening of Epigenetic Markers in Polycystic Ovary Syndrome. Front. Cell Dev. Biol. 2021 9 664843 10.3389/fcell.2021.664843 34113617
    [Google Scholar]
  72. Konieczna A. Rachoń D. Owczarek K. Kubica P. Kowalewska A. Kudłak B. Wasik A. Namieśnik J. Serum bisphenol A concentrations correlate with serum testosterone levels in women with polycystic ovary syndrome. Reprod. Toxicol. 2018 82 32 37 10.1016/j.reprotox.2018.09.006 30266220
    [Google Scholar]
  73. Kumar R. Minerva S. Shah R. Bhat A. Verma S. Chander G. Bhat G.R. Thapa N. Bhat A. Wakhloo A. Ganie M.A. Role of genetic, environmental, and hormonal factors in the progression of PCOS: A review. J. Reprod. Health Med. 2022 3 3 10.25259/JRHM_16_2021
    [Google Scholar]
  74. Priya K. Setty M. Babu U.V. Pai K.S.R. Implications of environmental toxicants on ovarian follicles: How it can adversely affect the female fertility? Environ. Sci. Pollut. Res. Int. 2021 28 48 67925 67939 10.1007/s11356‑021‑16489‑4 34628616
    [Google Scholar]
  75. Tong C. Wu Y. Zhang L. Yu Y. Insulin resistance, autophagy and apoptosis in patients with polycystic ovary syndrome: Association with PI3K signaling pathway. Front. Endocrinol. 2022 13 1091147 10.3389/fendo.2022.1091147 36589825
    [Google Scholar]
  76. Kaur S. Archer K.J. Devi M.G. Kriplani A. Strauss J.F. Singh R. Differential gene expression in granulosa cells from polycystic ovary syndrome patients with and without insulin resistance: Identification of susceptibility gene sets through network analysis. J. Clin. Endocrinol. Metab. 2012 97 10 E2016 E2021 10.1210/jc.2011‑3441 22904171
    [Google Scholar]
  77. Wang K. Li Y. Signaling pathways and targeted therapeutic strategies for polycystic ovary syndrome. Front. Endocrinol. 2023 14 1191759 10.3389/fendo.2023.1191759 37929034
    [Google Scholar]
  78. Zhang W. Thompson B.J. Hietakangas V. Cohen S.M. MAPK/ERK signaling regulates insulin sensitivity to control glucose metabolism in Drosophila. PLoS Genet. 2011 7 12 1002429 10.1371/journal.pgen.1002429 22242005
    [Google Scholar]
  79. Gao Y. Chen J. Ji R. Ding J. Zhang Y. Yang J. USP25 regulates the proliferation and apoptosis of ovarian granulosa cells in polycystic ovary syndrome by modulating the pi3k/akt pathway via deubiquitinating PTEN. Front. Cell Dev. Biol. 2021 9 779718 10.3389/fcell.2021.779718 34805185
    [Google Scholar]
  80. Abuelezz N.Z. Shabana M.E. Abdel-Mageed H.M. Rashed L. Morcos G.N.B. Nanocurcumin alleviates insulin resistance and pancreatic deficits in polycystic ovary syndrome rats: Insights on PI3K/AkT/mTOR and TNF-α modulations. Life Sci. 2020 256 118003 10.1016/j.lfs.2020.118003 32589998
    [Google Scholar]
  81. De Felici M. Klinger F.G. Pi3k/pten/akt signaling pathways in germ cell development and their involvement in germ cell tumors and ovarian dysfunctions. Int. J. Mol. Sci. 2021 22 18 9838 10.3390/ijms22189838 34575999
    [Google Scholar]
  82. Gong Y. Luo S. Fan P. Zhu H. Li Y. Huang W. Growth hormone activates PI3K/Akt signaling and inhibits ROS accumulation and apoptosis in granulosa cells of patients with polycystic ovary syndrome. Reprod. Biol. Endocrinol. 2020 18 1 121 10.1186/s12958‑020‑00677‑x 33287836
    [Google Scholar]
  83. Guo R. Zheng H. Li Q. Qiu X. Zhang J. Cheng Z. Melatonin alleviates insulin resistance through the PI3K/AKT signaling pathway in ovary granulosa cells of polycystic ovary syndrome. Reprod. Biol. 2022 22 1 100594 10.1016/j.repbio.2021.100594 34953312
    [Google Scholar]
  84. Jung W. Choi H. Kim J. Kim J. Kim W. Nurkolis F. Kim B. Effects of natural products on polycystic ovary syndrome: From traditional medicine to modern drug discovery. Heliyon 2023 9 10 20889 10.1016/j.heliyon.2023.e20889 37867816
    [Google Scholar]
  85. Rabah H.M. Mohamed D.A. Mariah R.A. Abd El-Khalik S.R. Khattab H.A. AbuoHashish, N.A.; Abdelsattar, A.M.; Raslan, M.A.; Farghal, E.E.; Eltokhy, A.K. Novel insights into the synergistic effects of selenium nanoparticles and metformin treatment of letrozole - induced polycystic ovarian syndrome: Targeting PI3K/Akt signalling pathway, redox status and mitochondrial dysfunction in ovarian tissue. Redox Rep. 2023 28 1 2160569 10.1080/13510002.2022.2160569 36661246
    [Google Scholar]
  86. Wu C. Jiang F. Wei K. Jiang Z. Exercise activates the PI3K-AKT signal pathway by decreasing the expression of 5α-reductase type 1 in PCOS rats. Sci. Rep. 2018 8 1 7982 10.1038/s41598‑018‑26210‑0
    [Google Scholar]
  87. Choi J. Jo M. Lee E. Choi D. AKT is involved in granulosa cell autophagy regulation via mTOR signaling during rat follicular development and atresia. Reproduction 2014 147 1 73 80 10.1530/REP‑13‑0386 24131573
    [Google Scholar]
  88. Li D. You Y. Bi F.F. Zhang T.N. Jiao J. Wang T.R. Zhou Y.M. Shen Z.Q. Wang X.X. Yang Q. Autophagy is activated in the ovarian tissue of polycystic ovary syndrome. Reproduction 2018 155 1 85 92 10.1530/REP‑17‑0499 29030491
    [Google Scholar]
  89. Fukuda S. Orisaka M. Tajima K. Hattori K. Kotsuji F. Luteinizing hormone-induced Akt phosphorylation and androgen production are modulated by MAP Kinase in bovine theca cells. J. Ovarian Res. 2009 2 1 17 10.1186/1757‑2215‑2‑17 19917087
    [Google Scholar]
  90. Yuanyuan C. Ningyu S. Lu L. Wuwen Z. Kai L. Yanting L. Junlan H. Xiang C. Jing Z. Hua Y. Ping Y. Transcriptomic analysis of theca cells in a PCOS rat model: Insights into follicular development. J. Ovarian Res. 2025 18 1 135 10.1186/s13048‑025‑01663‑w 40544268
    [Google Scholar]
  91. Diamanti-Kandarakis E. Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. Endocr. Rev. 2012 33 6 981 1030 10.1210/er.2011‑1034 23065822
    [Google Scholar]
  92. Liang Y.J. Yang W.X. Kinesins in MAPK cascade: How kinesin motors are involved in the MAPK pathway? Gene 2019 684 1 9 10.1016/j.gene.2018.10.042 30342167
    [Google Scholar]
  93. Zhang W. Liu H.T. Tu H. Cell research. 2002 Available from: http://www.cell-research.com
  94. Seger R. Hanoch T. Rosenberg R. Dantes A. Merz W.E. Strauss J.F. Amsterdam A. The ERK signaling cascade inhibits gonadotropin-stimulated steroidogenesis. J. Biotech Biomed. 2023 6 1 1 12 10.26502/jbb.2642‑91280066 36970578
    [Google Scholar]
  95. Liu S. Jia Y. Meng S. Luo Y. Yang Q. Pan Z. Mechanisms of and potential medications for oxidative stress in ovarian granulosa cells: A review. Int. J. Mol. Sci. 2023 24 11 9205 10.3390/ijms24119205 37298157
    [Google Scholar]
  96. Guo F. Fernando T. Zhu X. Shi Y. The overexpression of neurokinin B–neurokinin 3 receptor system exerts direct effects on the ovary under PCOS‐like conditions to interfere with mitochondrial function. Am. J. Reprod. Immunol. 2023 89 3 13663 10.1111/aji.13663 36453600
    [Google Scholar]
  97. Liu Y. Li Z. Wang Y. Cai Q. Liu H. Xu C. Zhang F. IL-15 participates in the pathogenesis of polycystic ovary syndrome by affecting the activity of granulosa cells. Front. Endocrinol. 2022 13 787876 10.3389/fendo.2022.787876 35250857
    [Google Scholar]
  98. Ding L. Jiang L. Xing Z. Dai H. Wei J. Map4k4 is upregulated and modulates granulosa cell injury and oxidative stress in polycystic ovary syndrome via activating JNK/c-JUN pathway: An experimental study. Int. Immunopharmacol 2023 124Pt A110841 10.1016/j.intimp.2023.110841 37647682
    [Google Scholar]
  99. Kobayashi M. Yoshino O. Nakashima A. Ito M. Nishio K. Ono Y. Kusabiraki T. Kunitomi C. Takahashi N. Harada M. Hattori K. Orisaka M. Osuga Y. Saito S. Inhibition of autophagy in theca cells induces CYP17A1 and PAI-1 expression via ROS/p38 and JNK signalling during the development of polycystic ovary syndrome. Mol. Cell. Endocrinol. 2020 508 110792 10.1016/j.mce.2020.110792 32199904
    [Google Scholar]
  100. Zhang N. Liu X. Zhuang L. Liu X. Zhao H. Shan Y. Liu Z. Li F. Wang Y. Fang J. Berberine decreases insulin resistance in a PCOS rats by improving GLUT4: Dual regulation of the PI3K/AKT and MAPK pathways. Regul. Toxicol. Pharmacol. 2020 110 104544 10.1016/j.yrtph.2019.104544 31778716
    [Google Scholar]
  101. Jin J. Ma Y. Tong X. Yang W. Dai Y. Pan Y. Ren P. Liu L. Fan H.Y. Zhang Y. Zhang S. Metformin inhibits testosterone-induced endoplasmic reticulum stress in ovarian granulosa cells via inactivation of p38 MAPK. Hum. Reprod. 2020 35 5 1145 1158 10.1093/humrep/deaa077 32372097
    [Google Scholar]
  102. Lan C.W. Chen M.J. Tai K.Y. Yu D.C.W. Yang Y.C. Jan P.S. Yang Y.S. Chen H.F. Ho H.N. Functional microarray analysis of differentially expressed genes in granulosa cells from women with polycystic ovary syndrome related to MAPK/ERK signaling. Sci. Rep. 2015 5 1 14994 10.1038/srep14994 26459919
    [Google Scholar]
  103. Donaubauer E.M. Hunzicker-Dunn M.E. Extracellular Signal-regulated Kinase (ERK)-dependent phosphorylation of Y-Box-binding protein 1 (YB-1) enhances gene expression in granulosa cells in response to follicle-stimulating hormone (FSH). J. Biol. Chem. 2016 291 23 12145 12160 10.1074/jbc.M115.705368 27080258
    [Google Scholar]
  104. Qiu Z. Dong J. Xue C. Li X. Liu K. Liu B. Cheng J. Huang F. Liuwei Dihuang Pills alleviate the polycystic ovary syndrome with improved insulin sensitivity through PI3K/Akt signaling pathway. J. Ethnopharmacol. 2020 250 111965 10.1016/j.jep.2019.111965 31185267
    [Google Scholar]
  105. Zhao H. Dinh T.H. Wang Y. Yang Y. The roles of MAPK signaling pathway in ovarian folliculogenesis. J. Ovarian Res. 2025 18 1 152 10.1186/s13048‑025‑01737‑9 40660328
    [Google Scholar]
  106. Liu T. Zhang L. Joo D. Sun S.C. NF-κB signaling in inflammation. Signal Transduct. Target. Ther. 2017 2 17023 10.1038/sigtrans.2017.23
    [Google Scholar]
  107. Tan W. Zhang J. Dai F. Yang D. Gu R. Tang L. Liu H. Cheng Y. Insights on the NF-κB system in polycystic ovary syndrome, attractive therapeutic targets. Mol. Cell. Biochem. 2024 479 3 467 486 10.1007/s11010‑023‑04736‑w 37097332
    [Google Scholar]
  108. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb. Perspect. Biol. 2009 1 6 a001651 10.1101/cshperspect.a001651 20457564
    [Google Scholar]
  109. Deligeoroglou E. Vrachnis N. Athanasopoulos N. Iliodromiti Z. Sifakis S. Iliodromiti S. Siristatidis C. Creatsas G. Mediators of chronic inflammation in polycystic ovarian syndrome. Gynecol. Endocrinol. 2012 28 12 974 978 10.3109/09513590.2012.683082 22553983
    [Google Scholar]
  110. Ha L.X. Wu Y.Y. Yin T. Yuan Y.Y. Du Y.D. Effect of TNF-alpha on endometrial glucose transporter-4 expression in patients with polycystic ovary syndrome through nuclear factor-kappa B signaling pathway activation. J. Physiol. Pharmacol. 2021 72 6 965 973 35485360
    [Google Scholar]
  111. He Z. Wang Y. Zhuan L. Li Y. Tang Z. Wu Z. Ma Y. MIF-mediated NF-κB signaling pathway regulates the pathogenesis of polycystic ovary syndrome in rats. Cytokine 2021 146 155632 10.1016/j.cyto.2021.155632
    [Google Scholar]
  112. Guo Q. Jin Y. Chen X. Ye X. Shen X. Lin M. Zeng C. Zhou T. Zhang J. NF-κB in biology and targeted therapy: New insights and translational implications. Signal Transduct. Target. Ther. 2024 9 1 53 10.1038/s41392‑024‑01757‑9
    [Google Scholar]
  113. Tan W. Dai F. Yang D. Deng Z. Gu R. Zhao X. Cheng Y. MiR-93-5p promotes granulosa cell apoptosis and ferroptosis by the NF-kB signaling pathway in polycystic ovary syndrome. Front. Immunol. 2022 13 967151 10.3389/fimmu.2022.967151 36341347
    [Google Scholar]
  114. Koc O. Ozdemirici S. Acet M. Soyturk U. Aydin S. Nuclear factor-κB expression in the endometrium of normal and overweight women with polycystic ovary syndrome. J. Obstet. Gynaecol. 2017 37 7 924 930 10.1080/01443615.2017.1315563 28617068
    [Google Scholar]
  115. Ahmed S.M.U. Luo L. Namani A. Wang X.J. Tang X. Nrf2 signaling pathway: Pivotal roles in inflammation. Biochim. Biophys. Acta Mol. Basis Dis. 2017 1863 2 585 597 10.1016/j.bbadis.2016.11.005 27825853
    [Google Scholar]
  116. Ghantabpour T. Goudarzi N. Parsaei H. Overview of Nrf2 as a target in ovary and ovarian dysfunctions focusing on its antioxidant properties. J. Ovarian Res. 2025 18 1 60 10.1186/s13048‑025‑01639‑w 40121445
    [Google Scholar]
  117. Baird L. Yamamoto M. The molecular mechanisms regulating the KEAP1-NRF2 pathway. Mol. Cell. Biol. 2020 40 13 e00099 e20 10.1128/MCB.00099‑20 32284348
    [Google Scholar]
  118. Zhang J. Wang X. Vikash V. Ye Q. Wu D. Liu Y. Dong W. ROS and ROS‐mediated cellular signaling. Oxid. Med. Cell. Longev. 2016 2016 1 4350965 10.1155/2016/4350965 26998193
    [Google Scholar]
  119. Lu J. Wang Z. Cao J. Chen Y. Dong Y. A novel and compact review on the role of oxidative stress in female reproduction. Reprod. Biol. Endocrinol. 2018 16 1 80 10.1186/s12958‑018‑0391‑5 30126412
    [Google Scholar]
  120. Kabel A.M. Al-Shehri A.H. Al-Talhi R.A. Abd Elmaaboud M.A. The promising effect of linagliptin and/or indole-3-carbinol on experimentally-induced polycystic ovarian syndrome. Chem. Biol. Interact. 2017 273 190 199 10.1016/j.cbi.2017.06.009 28619389
    [Google Scholar]
  121. Liu G.H. Qu J. Shen X. NF-κB/p65 antagonizes Nrf2-ARE pathway by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK. Biochim. Biophys. Acta Mol. Cell Res. 2008 1783 5 713 727 10.1016/j.bbamcr.2008.01.002 18241676
    [Google Scholar]
  122. Armagan G. Sevgili E. Gürkan F.T. Köse F.A. Bilgiç T. Dagcı T. Saso L. Regulation of the Nrf2 pathway by glycogen synthase kinase-3β in MPP+-induced cell damage. Molecules 2019 24 7 1377 10.3390/molecules24071377 30965670
    [Google Scholar]
  123. Medunjanin S. Schleithoff L. Fiegehenn C. Weinert S. Zuschratter W. Braun-Dullaeus R.C. GSK-3β controls NF-kappaB activity via IKKγ/NEMO. Sci. Rep. 2016 6 1 38553 10.1038/srep38553 27929056
    [Google Scholar]
  124. Saha S. Buttari B. Panieri E. Profumo E. Saso L. An overview of Nrf2 signaling pathway and its role in inflammation. Molecules 2020 25 22 5474 10.3390/molecules25225474 33238435
    [Google Scholar]
  125. Chen Y. Liu K. Zhang J. Hai Y. Wang P. Wang H. Liu Q. Wong C.C.L. Yao J. Gao Y. Liao Y. Tang X. Wang X.J. c‐Jun NH2‐terminal protein kinase phosphorylates the nrf2‐ech homology 6 domain of nuclear factor erythroid 2–related factor 2 and downregulates cytoprotective genes in acetaminophen‐induced liver injury in mice. Hepatology 2020 71 5 1787 1801 10.1002/hep.31116 31945188
    [Google Scholar]
  126. Butt M.A. Shafique H.M. Mustafa M. Moghul N.B. Munir A. Shamas U. Tabassum S. Kiyani M.M. Therapeutic potential of selenium nanoparticles on letrozole-induced polycystic ovarian syndrome in female wistar rats. Biol. Trace Elem. Res. 2023 201 11 5213 5229 10.1007/s12011‑023‑03579‑2 36694071
    [Google Scholar]
  127. Kyei G. Sobhani A. Nekonam S. Shabani M. Ebrahimi F. Qasemi M. Salahi E. Fardin A. Assessing the effect of MitoQ10 and Vitamin D3 on ovarian oxidative stress, steroidogenesis and histomorphology in DHEA induced PCOS mouse model. Heliyon 2020 6 7 04279 10.1016/j.heliyon.2020.e04279 32760818
    [Google Scholar]
  128. Yu K. Wang R.X. Li M.H. Sun T.C. Zhou Y.W. Li Y.Y. Sun L.H. Zhang B.L. Lian Z.X. Xue S.G. Liu Y.X. Deng S.L. Melatonin reduces androgen production and upregulates heme oxygenase-1 expression in granulosa cells from pcos patients with hypoestrogenia and hyperandrogenia. Oxid. Med. Cell. Longev. 2019 2019 1 13 10.1155/2019/8218650 31772710
    [Google Scholar]
  129. Wang Y. Li N. Zeng Z. Tang L. Zhao S. Zhou F. Zhou L. Xia W. Zhu C. Rao M. Humanin regulates oxidative stress in the ovaries of polycystic ovary syndrome patients via the Keap1/Nrf2 pathway. Mol. Hum. Reprod. 2021 27 2 gaaa081 10.1093/molehr/gaaa081 33337472
    [Google Scholar]
  130. Huang Y. Zhang X. Luteolin alleviates polycystic ovary syndrome in rats by resolving insulin resistance and oxidative stress. Am. J. Physiol. Endocrinol. Metab. 2021 320 6 E1085 E1092 10.1152/ajpendo.00034.2021 33900851
    [Google Scholar]
  131. Qu J. Qiu M. Wang J. Chen Z. Chen M. Teng X. Li Y. Fibroblast growth factor 19 regulates polycystic ovary syndrome progression via FGFR4-ERK-NRF2 pathway. Front. Cell Dev. Biol. 2025 13 1626938 10.3389/fcell.2025.1626938 40950398
    [Google Scholar]
  132. Loboda A. Damulewicz M. Pyza E. Jozkowicz A. Dulak J. Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: An evolutionarily conserved mechanism. Cell. Mol. Life Sci. 2016 73 17 3221 3247 10.1007/s00018‑016‑2223‑0 27100828
    [Google Scholar]
  133. Banerjee S. Cooney L.G. Stanic A.K. Immune dysfunction in polycystic ovary syndrome. Immunohorizons 2023 7 5 323 332 10.4049/immunohorizons.2200033 37195871
    [Google Scholar]
  134. Liu H. Jin L. Wang X. Shi J. He Y. Sun N. Yang F. Reactive oxygen species in polycystic ovary syndrome: Mechanistic insights into pathogenesis and therapeutic opportunities. Redox Biol. 2025 85 103776 10.1016/j.redox.2025.103776 40694958
    [Google Scholar]
  135. Taqi M.O. Saeed-Zidane M. Gebremedhn S. Salilew-Wondim D. Tholen E. Neuhoff C. Hoelker M. Schellander K. Tesfaye D. NRF2-mediated signaling is a master regulator of transcription factors in bovine granulosa cells under oxidative stress condition. Cell Tissue Res. 2021 385 3 769 783 10.1007/s00441‑021‑03445‑4 34008050
    [Google Scholar]
  136. Yuan J. Li Z. Yu Y. Wang X. Zhao Y. Natural compounds in the management of polycystic ovary syndrome: A comprehensive review of hormonal regulation and therapeutic potential. Front. Nutr. 2025 12 1520695 10.3389/fnut.2025.1520695 40008316
    [Google Scholar]
  137. González F. Nair K.S. Daniels J.K. Basal E. Schimke J.M. Blair H.E. Hyperandrogenism sensitizes leukocytes to hyperglycemia to promote oxidative stress in lean reproductive-age women. J. Clin. Endocrinol. Metab. 2012 97 8 2836 2843 10.1210/jc.2012‑1259 22569241
    [Google Scholar]
  138. Zhang R. Hu K. Bai H. Liu H. Pu Y. Yang C. Liu Q. Fan P. Increased oxidative stress is associated with hyperandrogenemia in polycystic ovary syndrome evidenced by oxidized lipoproteins stimulating rat ovarian androgen synthesis in vitro. Endocrine 2024 84 3 1238 1249 10.1007/s12020‑024‑03726‑2 38374513
    [Google Scholar]
  139. González F. Inflammation in polycystic ovary syndrome: Underpinning of insulin resistance and ovarian dysfunction. Steroids 2012 77 4 300 305 10.1016/j.steroids.2011.12.003
    [Google Scholar]
  140. Xing C. Zhang J. Zhao H. He B. Effect of sex hormone-binding globulin on polycystic ovary syndrome: Mechanisms, manifestations, genetics, and treatment. Int. J. Womens Health 2022 14 91 105 10.2147/IJWH.S344542 35140526
    [Google Scholar]
  141. Shi J. Hu K.L. Li X.X. Ge Y.M. Yu X.J. Zhao J. Bisphenol a downregulates GLUT4 expression by activating aryl hydrocarbon receptor to exacerbate polycystic ovary syndrome. Cell Commun. Signal. 2024 22 1 28 10.1186/s12964‑023‑01410‑y 38200540
    [Google Scholar]
  142. Huang F.M. Chang Y.C. Lee S.S. Yang M.L. Kuan Y.H. Expression of pro‐inflammatory cytokines and mediators induced by Bisphenol A via ERK‐NFκB and JAK1/2‐STAT3 pathways in macrophages. Environ. Toxicol. 2019 34 4 486 494 10.1002/tox.22702 30609183
    [Google Scholar]
  143. Celar Šturm D. Režen T. Jančar N. Virant-Klun I. Bisphenol a disrupts steroidogenesis and induces apoptosis in human granulosa cells cultured in vitro. Int. J. Mol. Sci. 2025 26 9 4081 10.3390/ijms26094081 40362320
    [Google Scholar]
  144. Kazemi M. Hadi A. Pierson R.A. Lujan M.E. Zello G.A. Chilibeck P.D. Effects of dietary glycemic index and glycemic load on cardiometabolic and reproductive profiles in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. Adv. Nutr. 2021 12 1 161 178 10.1093/advances/nmaa092 32805007
    [Google Scholar]
  145. Shang Y. Zhou H. Hu M. Feng H. Effect of diet on insulin resistance in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2020 105 10 3346 3360 10.1210/clinem/dgaa425 32621748
    [Google Scholar]
  146. Patten R.K. Boyle R.A. Moholdt T. Kiel I. Hopkins W.G. Harrison C.L. Stepto N.K. Exercise interventions in polycystic ovary syndrome: A systematic review and meta-analysis. Front. Physiol. 2020 11 606 10.3389/fphys.2020.00606 32733258
    [Google Scholar]
  147. Martin K.A. Chang R.J. Ehrmann D.A. Ibanez L. Lobo R.A. Rosenfield R.L. Shapiro J. Montori V.M. Swiglo B.A. Evaluation and treatment of hirsutism in premenopausal women: An endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2008 93 4 1105 1120 10.1210/jc.2007‑2437 18252793
    [Google Scholar]
  148. Curi D.D.G. Fonseca A.M. Marcondes J.A.M. Almeida J.A.M. Bagnoli V.R. Soares J.M. Baracat E.C. Metformin versus lifestyle changes in treating women with polycystic ovary syndrome. Gynecol. Endocrinol. 2012 28 3 182 185 10.3109/09513590.2011.583957 22309675
    [Google Scholar]
  149. Sathyapalan T. Hobkirk J.P. Javed Z. Carroll S. Coady A.M. Pemberton P. Smith A. Cianflone K. Atkin S.L. The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight/obese women with polycystic ovary syndrome. Front. Endocrinol. 2019 10 JUN 394 10.3389/fendo.2019.00394 31293514
    [Google Scholar]
  150. Zulian E. Sartorato P. Benedini S. Baro G. Armanini D. Mantero F. Scaroni C. Spironolactone in the treatment of polycystic ovary syndrome: Effects on clinical features, insulin sensitivity and lipid profile. J. Endocrinol. Invest. 2005 28 3 49 53 10.1007/BF03345529 15816371
    [Google Scholar]
  151. Moghetti P. Tosi F. Tosti A. Negri C. Misciali C. Perrone F. Caputo M. Muggeo M. Castello R. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: A randomized, double blind, placebo-controlled trial. J. Clin. Endocrinol. Metab. 2000 85 1 89 94 10.1210/jc.85.1.89 10634370
    [Google Scholar]
  152. Tian Q.J. Consensus on infertility management and fertility preservation related to polycystic ovary syndrome. Reprod. Devel Med. 2020 4 4 239 248 10.4103/2096‑2924.305930
    [Google Scholar]
  153. Shojaeian Z. Sadeghi R. Latifnejad Roudsari R. Calcium and vitamin D supplementation effects on metabolic factors, menstrual cycles and follicular responses in women with polycystic ocvary syndrome: A systematic review and meta-analysis. Caspian J. Intern. Med. 2019 10 4 359 369 31814932
    [Google Scholar]
  154. Rashid R. Mir S.A. Kareem O. Ali T. Ara R. Malik A. Amin F. Bader G.N. Polycystic ovarian syndrome-current pharmacotherapy and clinical implications. Taiwan. J. Obstet. Gynecol. 2022 61 1 40 50 10.1016/j.tjog.2021.11.009 35181044
    [Google Scholar]
  155. Singh S. Pal N. Shubham S. Sarma D.K. Verma V. Marotta F. Kumar M. Polycystic ovary syndrome: Etiology, current management, and future therapeutics. J. Clin. Med. 2023 12 4 1454 10.3390/jcm12041454 36835989
    [Google Scholar]
  156. Hu R. Huang Y. Liu Z. Dong H. Ma W. Song K. Xu X. Wu X. Geng Y. Li F. Zhang M. Song Y. Characteristics of polycystic ovary syndrome rat models induced by letrozole, testosterone propionate and high-fat diets. Reprod. Biomed. Online 2025 50 1 104296 10.1016/j.rbmo.2024.104296 39626468
    [Google Scholar]
  157. Stener-Victorin E. Update on animal models of polycystic ovary syndrome. Endocrinology 2022 163 12 bqac164 10.1210/endocr/bqac164 36201611
    [Google Scholar]
  158. Yang A.M. Cui N. Sun Y.F. Hao G.M. Letrozole for female infertility. Front. Endocrinol. 2021 12 676133 10.3389/fendo.2021.676133 34220713
    [Google Scholar]
  159. Liu H. Tu M. Yin Z. Zhang D. Ma J. He F. Unraveling the complexity of polycystic ovary syndrome with animal models. J. Genet. Genomics 2024 51 2 144 158 10.1016/j.jgg.2023.09.012 37777062
    [Google Scholar]
  160. Shah S.F. Noorali S. Faizi S. Jabeen A. Patuletin ameliorates inflammation and letrozole–induced polycystic ovarian syndrome in rats. Cell Biochem. Funct. 2024 42 7 4123 10.1002/cbf.4123 39294896
    [Google Scholar]
  161. Cheng X. He B. Clinical and biochemical potential of antioxidants in treating polycystic ovary syndrome. Int. J. Womens Health 2022 14 467 479 10.2147/IJWH.S345853 35392500
    [Google Scholar]
  162. Wei H. Zhang Z. Zhang S. Wang J. Cui X. Zhang Z. Yu J. Lei X. Xiuhong Z. Huo P. Resveratrol improves follicular development in PCOS rats by inhibiting the inflammatory response and pyroptosis of granulosa cells. Biol. Reprod. 2024 15 ioae160 10.1093/biolre/ioae160 39545777
    [Google Scholar]
  163. Bai Y. Liu Y. Wang Y. Liu X. Wang Y. Liu H. Yi H. Xu C. Zhang F. IL-18BP therapy ameliorates reproductive and metabolic phenotypes in a PCOS mouse model by relieving inflammation, fibrosis and endoplasmic reticulum stress. Reprod. Sci. 2024 31 11 3595 3608 10.1007/s43032‑024‑01631‑7 38977641
    [Google Scholar]
  164. Siddiqui S. Mateen S. Ahmad R. Moin S. A brief insight into the etiology, genetics, and immunology of polycystic ovarian syndrome (PCOS). J. Assist. Reprod. Genet. 2022 39 11 2439 2473 10.1007/s10815‑022‑02625‑7 36190593
    [Google Scholar]
  165. Jasaszwili M. Billert M. Strowski M.Z. Nowak K.W. Skrzypski M. Adropin as a fat-burning hormone with multiple functions—review of a decade of research. Molecules 2020 25 3 549 10.3390/molecules25030549 32012786
    [Google Scholar]
  166. Rizk F.H. El Saadany A.A. Elshamy A.M. Abd Ellatif R.A. El-Guindy D.M. Helal D.S. Hamama M.G. El-Sharnoby J.A.E.H. Abdel Ghafar M.T. Faheem H. Ameliorating effects of adropin on letrozole‐induced polycystic ovary syndrome via regulating steroidogenesis and the microbiota inflammatory axis in rats. J. Physiol. 2024 602 15 3621 3639 10.1113/JP285793 38980987
    [Google Scholar]
  167. Anima B. Gurusubramanian G. Roy V.K. Apelin receptor modulation mitigates letrozole-induced polycystic ovarian pathogenesis in mice. Cytokine 2024 179 156639 10.1016/j.cyto.2024.156639 38733946
    [Google Scholar]
  168. Yadav S. Dadge S. Garg R. Goand U.K. Agarwal A. Chauhan D. Gayen J.R. Pancreastatin inhibitor PSTi8 improves ovarian health in Letrozole-HFD induced PCOS rats by ameliorating metabolic and reproductive parameters. Steroids 2025 214 109558 10.1016/j.steroids.2024.109558 39742935
    [Google Scholar]
  169. Lohrasbi P. Karbalay-Doust S. Bagher Tabei S.M. Azarpira N. Alaee S. Rafiee B. Bahmanpour S. The effects of melatonin and metformin on histological characteristics of the ovary and uterus in letrozole-induced polycystic ovarian syndrome mice: A stereological study. Int. J. Reprod. Biomed. 2022 20 11 973 988 10.18502/ijrm.v20i11.12365 36618831
    [Google Scholar]
  170. Basheer M. Bhat A.H. Ahmad Hajam Y. Batiha G.E.S. Ataya F.S. Fouad D. Rai S. Melatonin as a promising therapeutic intervention for restoring ovarian function in letrozole-induced polycystic ovary syndrome rats. Heliyon 2023 9 11 21237 10.1016/j.heliyon.2023.e21237 38027664
    [Google Scholar]
  171. Prajapati D.P. Patel M. Dharamsi A. Beneficial effect of polyherbal formulation in letrozole induced Polycystic ovarian syndrome (PCOS). J. Tradit. Complement. Med. 2022 12 6 575 583 10.1016/j.jtcme.2022.08.003 36325242
    [Google Scholar]
  172. Yang W. Qiu J. Zi J. Li Y. Li J. Guo M. Zhou Y. Yang X. Lai Y. Effect of Rhei Radix Et Rhizome on treatment of polycystic ovary syndrome by regulating PI3K/AKT pathway and targeting EGFR/ALB in rats. J. Ethnopharmacol. 2025 338 Pt 1 119020 10.1016/j.jep.2024.119020 39491761
    [Google Scholar]
  173. Kalimuthu V. Chandran Manimegalai S. Venkatesan R. Krishnamoorthy S.P. Dey N. Ramesh T. Balamuthu K. Exploring the therapeutic potential of terminalia chebula retz. in alleviating the complications of letrozole-induced pcos in rat model. Reprod. Sci. 2025 32 3 836 853 10.1007/s43032‑025‑01813‑x 39939489
    [Google Scholar]
  174. Yang W. Ma Y. Wu Y. Lei X. Zhang J. Li M. Study on the effects of Mogroside V in inhibiting NLRP3-mediated granulosa cell pyroptosis and insulin resistance to improve PCOS. J. Ovarian Res. 2025 18 1 10 10.1186/s13048‑024‑01563‑5 39838421
    [Google Scholar]
  175. Zhu H. Wu Y. Zhuang Z. Xu J. Chen F. Wang Q. Tang Q. Ampelopsis japonica aqueous extract improves ovulatory dysfunction in PCOS by modulating lipid metabolism. Biomed. Pharmacother. 2024 170 116093 10.1016/j.biopha.2023.116093 38159378
    [Google Scholar]
  176. Moustafa M.A. Mohamed A.S. Dakrory A.I. Abdelaziz M.H. Lepidium sativum extract alleviates reproductive and developmental toxicity in polycystic ovary syndrome induced by letrozole and high-fat diet in rats. Reprod. Sci. 2022 32 4 1338 1361 10.1007/s43032‑025‑01820‑y
    [Google Scholar]
  177. V Gadhave P. V Sutar G. Sajane S.J. Redasani V.K. Das K. Prasad P D. Alobid, S.; Ibrahim Almoteer, A.; Imam Rabbani, S.; Yasmin, F.; Gilkaramenthi, R.; Abdulrazaq AlAnazi, M.; Jameel Alshamrani, H.; Asdaq, S.M.B. Protective effects of vanillic acid on letrozole-induced polycystic ovarian syndrome: A comprehensive study in female wistar rats. Saudi Pharm. J. 2024 32 2 101953 10.1016/j.jsps.2024.101953 38288132
    [Google Scholar]
  178. Saad M.A. Rastanawi A.A. El-Sahar A.E. A Z El-Bahy A Ascorbic acid Mitigates behavioural disturbances associated with letrozole-induced PCOS via switching-off JAK2/STAT5 and JAK2/ERK1/2 pathways in rat hippocampus. Steroids 2025 213 109528 10.1016/j.steroids.2024.109528 39528020
    [Google Scholar]
  179. Yahia Z. Yahia A. Abdelaziz T. N-acetylcysteine clinical applications. Cureus 2024 16 10 72252 39450216
    [Google Scholar]
  180. Fang Y.Q. Ding H. Li T. Zhao X.J. Luo D. Liu Y. Li Y. N-acetylcysteine supplementation improves endocrine-metabolism profiles and ovulation induction efficacy in polycystic ovary syndrome. J. Ovarian Res. 2024 17 1 205 10.1186/s13048‑024‑01528‑8 39415242
    [Google Scholar]
  181. Salehi S. Allahverdy J. Pourjafar H. Sarabandi K. Jafari S.M. Gut microbiota and polycystic ovary syndrome (PCOS): Understanding the pathogenesis and the role of probiotics as a therapeutic strategy. Probiotics Antimicrob. Proteins 2024 16 5 1553 1565 10.1007/s12602‑024‑10223‑5 38421576
    [Google Scholar]
  182. Olaniyi K.S. Okara D.O. Areloegbe S.E. Suppression of adipose TGF-β1 by probiotics alleviates metabolic disturbance in experimentally induced PCOS. Prostaglandins Other Lipid Mediat. 2025 178 106989 10.1016/j.prostaglandins.2025.106989 40154941
    [Google Scholar]
  183. Areloegbe S.E. Obong N.N. Badejogbin O.C. Oniyide A.A. Ajadi I.O. Atuma C.L. Ajadi M.B. Adelekan O.E. Olaniyi K.S. Probiotics ameliorates hypothalamic amenorrhea in a rat model of PCOS. Metab. Brain Dis. 2025 40 3 145 10.1007/s11011‑025‑01573‑2 40072661
    [Google Scholar]
  184. Sarvestani M. Rajabzadeh A. Mazoochi T. Samimi M. Navari M. Moradi F. Use of placental-derived mesenchymal stem cells to restore ovarian function and metabolic profile in a rat model of the polycystic ovarian syndrome. BMC Endocr. Disord. 2024 24 1 154 10.1186/s12902‑024‑01688‑0 39160512
    [Google Scholar]
  185. Gautam R. Maan P. Jyoti A. Kumar A. Malhotra N. Arora T. The role of lifestyle interventions in pcos management: A systematic review. Nutrients 2025 17 2 310 10.3390/nu17020310 39861440
    [Google Scholar]
  186. Zhao B. Wu H. Yao Q. Bai W. Kang J. A ketogenic diet alleviates the apoptosis of granulosa cells by inhibiting the activation of cGAS-STING signaling pathway in PCOS mice. Cell Commun. Signal. 2024 22 1 568 10.1186/s12964‑024‑01939‑6 39604996
    [Google Scholar]
  187. Soltaninejad F. Shafiei G. Rafie F. Nematollahi-Mahani S.N. Pourjafari F. Haghpanah T. Afarinesh M.R. Ovarian epigenetics modifications following lifestyle interventions by exercise and alternate-day feeding in letrozole-induced PCOS rats. Sci. Rep. 2025 15 1 25557 10.1038/s41598‑025‑09264‑9 40664896
    [Google Scholar]
/content/journals/cpb/10.2174/0113892010433981251031050335
Loading
Polycystic Ovarian Syndrome (PCOS): A Brief Overview on Pathogenesis, Main Signaling Pathways, and Recent Studies Performed on Letrozoleinduced PCOS in Rodents
Bentham Science Publishers ; https://doi.org/10.2174/0113892010433981251031050335
/content/journals/cpb/10.2174/0113892010433981251031050335
/content/journals/cpb/10.2174/0113892010433981251031050335
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: PI3K-AKT ; insulin resistance ; letrozole ; and MAPK ; PCOS ; hyperandrogenism

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test